Trupan is indicated where suppression of acid secretion has therapeutic benefit; i.e
Pantoprazole is a proton pump inhibitor that suppresses the final step in gastric acid production by covalently binding to the H+/K+ATPase enzyme system at the surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus that persists longer than 24 hours.
No significant drug interactions have been observed in clinical studies.
Pantoprazole is contraindicated in patients with known hypersensitivity to any of the components of the formulation.
Trupan is well tolerated in both short-term and long-term treatment. Headache and diarrhea are the common side effects and rarely included side effects are abdominal pain, flatulence, rash, insomnia and hyperglycemia.
US FDA Pregnancy Category of Pantoprazole is B. There are, however, no adequate and well-controlled studies in pregnant woman.
Patients should be cautioned that Trupan tablet should not be split, chewed or crushed. Long-term therapy of Trupan may lead to malabsorption of cyanocobalamin (Vitamin B12) or may increase the risk of osteoporosis related disorders.
There are no known symptoms of overdosage in humans. Since Trupan is highly protein bound, it is not readily dialyzable. Apart from symptomatic and supportive management, no specific therapy is recommended.
Proton Pump Inhibitor
Keep in a dry place, away from light and heat. Keep out of the reach of children.